MA46358B1 - Compositions pharmaceutiques d'antagoniste de 5-ht6 - Google Patents

Compositions pharmaceutiques d'antagoniste de 5-ht6

Info

Publication number
MA46358B1
MA46358B1 MA46358A MA46358A MA46358B1 MA 46358 B1 MA46358 B1 MA 46358B1 MA 46358 A MA46358 A MA 46358A MA 46358 A MA46358 A MA 46358A MA 46358 B1 MA46358 B1 MA 46358B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
antagonist
methyl
pharmaceutically acceptable
relates
Prior art date
Application number
MA46358A
Other languages
English (en)
Inventor
Ramakrishna Nirogi
Venkateswarlu Jasti
Koteshwara Mudigonda
Dhanunjay Kumar Dogiparti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MA46358B1 publication Critical patent/MA46358B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

La présente invention concerne une composition pharmaceutique à libération immédiate (ir) comprenant du 1-[(2-bromophényl)sulfonyl]-5-méthoxy-3-[(4-méthyl-1-pipérazinyl) méthyl]-1h-indole ou un ou des sel(s) pharmaceutiquement acceptable(s) et un ou plusieurs excipients pharmaceutiquement acceptables. La présente invention concerne également des procédés de préparation desdites compositions pharmaceutiques.
MA46358A 2016-10-03 2017-09-29 Compositions pharmaceutiques d'antagoniste de 5-ht6 MA46358B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641033741 2016-10-03
PCT/IB2017/056009 WO2018065869A1 (fr) 2016-10-03 2017-09-29 Compositions pharmaceutiques d'antagoniste de 5-ht6

Publications (1)

Publication Number Publication Date
MA46358B1 true MA46358B1 (fr) 2021-08-31

Family

ID=60245136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46358A MA46358B1 (fr) 2016-10-03 2017-09-29 Compositions pharmaceutiques d'antagoniste de 5-ht6

Country Status (25)

Country Link
US (1) US20190336497A1 (fr)
EP (1) EP3518905B1 (fr)
JP (1) JP6669937B2 (fr)
KR (1) KR102083135B1 (fr)
CN (1) CN109789098A (fr)
AU (1) AU2017339755B2 (fr)
BR (1) BR112019006588A2 (fr)
CA (1) CA3038620C (fr)
CY (1) CY1124539T1 (fr)
DK (1) DK3518905T3 (fr)
EA (1) EA036235B1 (fr)
ES (1) ES2879675T3 (fr)
HR (1) HRP20211092T1 (fr)
HU (1) HUE055452T2 (fr)
IL (1) IL265662B (fr)
LT (1) LT3518905T (fr)
MA (1) MA46358B1 (fr)
MD (1) MD3518905T2 (fr)
MX (1) MX2019003815A (fr)
PL (1) PL3518905T3 (fr)
PT (1) PT3518905T (fr)
RS (1) RS62113B1 (fr)
SI (1) SI3518905T1 (fr)
WO (1) WO2018065869A1 (fr)
ZA (1) ZA201901734B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3648765A1 (fr) * 2017-07-03 2020-05-13 Suven Life Sciences Limited Nouvelles utilisations d'un antagoniste du récepteur 5-ht6 pur

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818508B1 (ko) 2002-11-28 2008-03-31 수벤 라이프 사이언시스 리미티드 세로토닌 수용체 친화력을 가지는 엔-아릴술포닐-3-치환인돌, 그 제조방법 및 그를 포함하는 약제학적 조성물
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
DK3077375T3 (en) * 2013-12-02 2017-09-11 Suven Life Sciences Ltd PROCEDURE FOR LARGE SCALE PREPARATION OF 1 - [(2-BROMPHENYL) SULPHONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE

Also Published As

Publication number Publication date
CA3038620A1 (fr) 2018-04-12
KR20190050858A (ko) 2019-05-13
EA036235B1 (ru) 2020-10-16
HRP20211092T1 (hr) 2021-10-15
IL265662A (en) 2019-05-30
SI3518905T1 (sl) 2021-11-30
EP3518905A1 (fr) 2019-08-07
US20190336497A1 (en) 2019-11-07
DK3518905T3 (da) 2021-07-19
MD3518905T2 (ro) 2021-09-30
IL265662B (en) 2019-11-28
EA201990827A1 (ru) 2019-07-31
LT3518905T (lt) 2021-08-10
AU2017339755B2 (en) 2019-11-07
NZ752060A (en) 2020-09-25
CY1124539T1 (el) 2022-07-22
ES2879675T3 (es) 2021-11-22
JP6669937B2 (ja) 2020-03-18
BR112019006588A2 (pt) 2019-07-02
CN109789098A (zh) 2019-05-21
PL3518905T3 (pl) 2021-10-25
PT3518905T (pt) 2021-07-14
EP3518905B1 (fr) 2021-04-28
RS62113B1 (sr) 2021-08-31
HUE055452T2 (hu) 2021-11-29
MX2019003815A (es) 2019-08-12
ZA201901734B (en) 2020-11-25
KR102083135B1 (ko) 2020-02-28
JP2019529471A (ja) 2019-10-17
AU2017339755A1 (en) 2019-04-18
WO2018065869A1 (fr) 2018-04-12
CA3038620C (fr) 2020-05-26

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA41256B1 (fr) Dosage spécifique de site d'un inhibiteur de btk
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA53126B1 (fr) Agents de dégradation sélectifs du récepteur des oestrogènes
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
EA202190153A1 (ru) Составы ингибитора axl/mer
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
MA46358B1 (fr) Compositions pharmaceutiques d'antagoniste de 5-ht6
MA46266B1 (fr) Formes cristallines
WO2015119924A3 (fr) Combinaisons à dose fixe de composés antiviraux
MA45002B1 (fr) Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda
MA34130B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
EA202190328A1 (ru) Фармацевтическая композиция, содержащая тикагрелор
WO2019151964A3 (fr) Formulations de saxagliptine à délitement buccal
MX2020007494A (es) Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas.
MA45990A (fr) Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7